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Abstract: Calcium phosphate-based cements with enhanced regenerative potential are promising 
biomaterials for the healing of bone defects. With a view to the use of such cements for low load 
bearing applications such as sinus augmentation or filling extraction sites, we have prepared α-
tricalcium phosphate (α-TCP)-based bone cements including materials that we would expect to 
improve their regenerative potential, and describe the mechanical properities of the resulting 
formulations herein. Formulations incorporated α-TCP, hydroxyapatite, biopolymer-thickened 
wetting agents, sutures, and platelet poor plasma. The mechanical properties of the composites 
were composition dependent, and optimized formulations had clinically relevant mechanical 
properties. Such calcium phosphate-based cements have potential as replacements for cements 
such as those based on polymethylmethacrylate (PMMA). 
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The development of implantable biodegradable materials is of great importance for regenerative 
medical technologies (i.e., drug delivery devices and tissue scaffolds).1-4 Biomaterials capable of 
conforming to patient-specific cavities are particularly desirable and have broad applicability in 
vivo for tissues with a variety of different mechanical properties.1-4  For example, hydrogels with 
low compressive moduli are useful for central and peripheral nervous tissue engineering, 
whereas cements with relatively high compressive moduli are applicable to bone tissue 
engineering.1-4  Consequently, moldable biomaterials such as these have the potential to be off-
the-shelf personalized medical treatments that can adapt to fill arbitrary three-dimensional shapes 
by adapting to conform to cavities within specific patients.1-4 
Bones are hierarchically structured composite materials5 that are predominantly composed of 
collagen and hydroxyapatite (a form of calcium phosphate), and this hard mineral protects softer 
vascularized cell-rich tissue that is embedded within the bone. There is great demand for 
biomaterials for the repair of bone defects, with more than 500,000 patients treated annually in 
the United States alone, and the market for such products is worth more than $2.5 billion.6 
Consequently, a variety of materials for bone tissue engineering have been developed, of which, 
calcium phosphate-based cements are one class.2, 3, 7-16Ideally, the mechanical properties 
(modulus and strength) for materials intended to replace/repair bone should mimic those of the 
natural bone. For low load bearing applications such as sinus augmentation or filling extraction 
sites, the strength is of minimal importance, and the Young’s modulus should be ca. 0.05-
1GPa.17 For medium load bearing applications such as alveolar cleft repairs, alveolar ridge 
augmentations and calvarian repairs, the strength would ideally be above 50 MPa and the 
modulus ca. 1 GPa; whereas for high load bearing applications such as segmental 
mandibular/tibial defect repair or cervical disk repair, the strength should be greater than 150 
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MPa and the modulus ca. 10-30 GPa.17 Calcium phosphate-based cements are one class of 
materials under investigation for such applications because of their ease of formulation and 
application.18,19 
While there are a variety of PMMA-based and calcium phosphate based cements available, 
PMMA-based cements are known to trigger apoptosis in the tissue surrounding the site of 
application because the setting process is exothermic.20,21 Furthermore, PMMA-based cements 
are not biodegradable, and consequently cannot be remodeled in vivo to form a fully integrated 
section of functional bone tissue. Calcium phosphate-based cements22-29 represent an attractive 
alternative to PMMA-based cements20,21 because they can be remodeled, integrate well with 
bone, and generate little heat in setting. There are many formulations of calcium phosphate 
cements (CPC) reported in the literature, and appropriately designed formulations have 
compressive strengths and compressive moduli that can be used for low, medium or high load-
bearing applications.18,19 The inclusion of fibers in CPC formulations is typically intended to 
reinforce the cement, but fibers that are too short can reduce the strength and modulus of these 
formulations by acting as a site from which crack propagation can occur.18,19 We sought to 
design a regenerative CPC formulation suitable for filling bone defects exposed to low 
compressive loads (e.g., sinus augmentation, filling extraction sites).17-19 
In contrast to the CPC variants available, we investigated composites with the potential to impart 
long term macroporosity, incorporate healing cofactors from plasma, and expedite bone 
ingrowth/remodeling.28 To achieve these goals, we investigate CPC formulations based on α-
tricalcium phosphate (α-TCP) and hydroxyapatite. Using these base components, we observe the 
mechanical effects of introducing biopolymer-thickened wetting agents, blood plasma wetting 
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agents, and biodegradable polymer-based sutures (that in the long-term should degrade leaving 
pores to expedite bone ingrowth and remodeling). We report herein a variety of previously 
unreported low cost CPC formulations mechanical properties suitable for low load bearing 
applications. 
MATERIALS AND METHODS 
Materials and Synthetic/Analytical Methods 
Unless otherwise stated, all chemicals were of ACS grade, purchased from Sigma-Aldrich and 
used as received without further purification. Oasis Monofyl® 4-0 biodegradable sutures 
(SouthPointe Surgical Supply, Inc., FL), and polyglycolic acid (PGA) 4-0 biodegradable sutures 
were purchased from (Suture Direct, IL). 4-0 sutures have diameters of 150 µm and were cut to 
lengths of 5 mm with a razor blade. Platelet poor plasma (PPP) was isolated via centrifugation of 
human whole blood (South Texas Tissue Center, TX) at 2000 g for 5 minutes. 
Preparation of α-TCP 
α-TCP was prepared via the solid state reaction between calcium carbonate (1 molar equivalent) 
and dibasic calcium phosphate dihydrate (two molar equivalents) in accordance with the 
literature.30 Reagents were shaken at 10 Hz for 30 minutes using a Mixer Mill MM 300 (Retsch 
GmbH, Germany) with a stainless steel ball bearing grinding chamber using one stainless steel 
ball of 1” in diameter.  The resulting powders were heated under vacuum at a rate of 1000 oC /hr, 
held at 1200 oC for 12 hours in a graphite-lined furnace (Furnace Source LLC, CT), and 
subsequently allowed to cool under vacuum in the furnace to 300 oC before opening the oven and 
allowing the material to cool to room temperature in air. The resulting solid was analyzed via 
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Fourier Transform Infrared Spectroscopy (FTIR) and X-Ray Diffraction (XRD). The remainder 
of the α-TCP was ground into a coarse powder using a mortar and pestle, prior to grinding for 30 
minutes using a Mixer Mill MM 300 (Retsch GmbH, Germany) with a stainless steel ball bearing 
grinding chamber using one stainless ball of 1” in diameter and shaking at 10 Hz, yielding a 
finely ground powder. 
Fourier Transform Infrared Spectroscopy (FTIR) 
Infrared spectroscopy was carried out on a JASCO FTIR 4100 Spectrometer (Thermo Fisher 
Scientific Inc., USA). Spectra were recorded for 128 scans at 21 oC, with a 1 cm-1 resolution. 
Absorbance spectra of KBr discs were recorded in transmission mode, as were spectra of the 
pure solid powder in attenuated total reflectance (ATR) mode. Spectra were corrected for 
background and atmosphere using the software provided with the spectrometer. 
X-ray Diffraction (XRD) 
XRD data was collected on a Rigaku R-Axis Spider diffractometer with an image plate detector 
using a graphite monochromator with CuKα radiation (λ = 1.5418 Å) at room temperature. The 
instrument was controlled using Rapid/XRD diffractometer control software (Rapid/XRD 
Version 2.3.8., Rigaku Americas Corporation, The Woodlands, TX).  The step size in 2Ɵ 
(degrees) was 0.01, and the acquisition time per step was 0.2 seconds. The integration of the two 
dimensional data into a one dimensional pattern was accomplished using 2DP (2DP Version 1.0., 
Rigaku Americas Corporation, The Woodlands, TX). All XRD pattern analysis was performed 
using JADE software (MDI, v 8.1). 
Particle size analysis 
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Milled powder was mounted on a Scanning Electron Microscopy (SEM) stub and sputter coated 
with Pt/Pd (15 nm). All powders were imaged using a Zeiss Supra 40 VP field emission scanning 
electron microscope. The ImageJ analyze particle command was used to calculate surface area of 
particles from each of four SEM images after first subtracting the background with a Gaussian 
blur filter, normalizing the contrast, applying a mean filter, and creating a binary image. Prism 
was used to re-express data as the log10 (particle size in µm2), to create a histogram of this data, 
and to fit a normal curve to the distribution data. Since the particle geometry is observed to be 
irregular, when reporting metrics relevant to the normal curve we converted data back to a non-
logarithmic scale and report surface area. To more easily conceptualize these values, we also 
report a particle diameter by assuming a circular geometry. 
CPC Preparation 
Cements were prepared by mixing wetting agents including biopolymer-based thickeners 34 wt 
% (of various compositions, Table 1) and calcium phosphates 66 wt % (typically composed from 
α-TCP (98 wt %) and hydroxyapatite (2 wt %)), with the optional addition of biodegradable 
sutures (up to 1.5 wt %). Wetting agents were composed of an aqueous solution of disodium 
phosphate (4 wt %) to which was added various combinations of carboxymethyl cellulose 
sodium salt (CMC, MW 700 kDa, 1 wt % in disodium phosphate solution, corrected to pH 7.4 
with 1M HCl) or bovine gelatin (1 wt % in disodium phosphate solution) and platelet poor 
plasma (PPP). The precise compositions of each cement are presented in Table 1. Cements were 
mixed for at least 20 seconds in a glass Petri dish prior to packing into a BD syringe (3 mL, ca. 
8.3 mm internal diameter) with its tip removed which is analogous to the methodology used to 
prepare dental putty prior to packing them into patient-specific dental cavities. The syringes were 
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rendered air-tight with a rubber stopper that prevented evaporation and incubated at 37 oC for 24 
hours to allow the cement to set. After 24 hours the cylinders were cut into segments of 12 mm 
in length for mechanical testing or 2.5 mm for in vitro degradation studies using a razor blade. 
Mechanical Testing 
The compressive moduli and strengths of the cement formulations were assessed using an 
Instron Materials Testing Machine 5543 (Instron, Norwood, MA). Compressive extension tests 
were performed at 21 oC using a load cell weight of 5 kN and a deformation rate of 0.05 mm s-1, 
slightly faster than similar studies to account for the larger load cell.31, 32 Cylindrical testing 
specimens for compressive extension tests were 8.3 mm in diameter and 12 mm in height, which 
is within the range of comparable CPCs reported in the literature.31-33 Compressive moduli, 
compressive strengths, and moduli of resilience were determined and plotted using R 
(http://www.r-project.org/). Statistical analysis via ANOVA was also carried out within R: one 
way ANOVA statistics were calculated and interpreted with Tukey’s multiple comparison test.  
In Vitro Degradation 
Precisely weighed sections of cements were incubated in phosphate-buffered saline (PBS) at 37 
oC and their masses recorded daily for two weeks. 
RESULTS 
Synthesis 
α-TCP was prepared via the solid state reaction between calcium carbonate and dibasic calcium 
phosphate dehydrate. Analysis of the resulting solid with FTIR and XRD confirmed that the 
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correct polymorph was formed during the solid state reaction. The FTIR spectrum the KBr disc 
of α-TCP (Figure 1 A) recorded in transmission mode showed a broad band at ca. 1055-954 cm-1 
that is associated with symmetric P-O stretching and triply degenerate anti-symmetric P-O 
stretching; the broad band at 551-613 cm-1 is associated with triply degenerate anti-symmetric P-
O bending, and the shoulder at 471 cm-1 and the clearly discernable band at 430 cm-1 is 
associated with symmetric P-O stretching that are all characteristic of α-TCP.34 Furthermore, the 
FTIR spectrum of pure α-TCP (Figure 1 B) recorded in ATR mode revealed clearly discernable 
peaks at 1077, 1085, 1027, 1012 and 998 cm-1 corresponding to the triply degenerate anti-
symmetric P-O stretching, and 976, 964 and 954 cm-1 corresponding to the symmetric P-O 
stretching, that are all characteristic of α-TCP.34-36 The XRD spectrum of α-TCP (Figure 1 C) 
revealed clear peaks at 2ϴ = 12.101, 14.026, 15.169, 17.094, 22.138, 22.675, 22.890, 24.105, 
29.665, 3.0346, 30.709, 31.260, 32.089, 32.208, 34.209, 34.466, 36.434, 37.784, 38.94, 39.91 
that are characteristic of α-TCP. 34, 37  
Powder preparation 
Prior to inclusion in the cement formulations, the α-TCP was ground first with a mortar and 
pestle and subsequently with a Mixer Mill MM 300 in a ball bearing grinding chamber. The 
resulting finely ground powder (Figure 2 and S1) was composed of irregularly shaped particles 
with a lognormal distribution (R-squared of 62.6%). After conversion to a non-logarithmic scale, 
the 95% confidence interval of mean particle surface area ranged from 100 to 428 µm2 (Figure 
S2). While the particle sizes and shapes were irregular, the particle diameters were 10 to 20.7 µm 
at the 95% confidence interval if the particles were assumed to be spherical. 
Characteristics of the CPCs 
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Cement formulations were mixed, and all mechanical properties reported were recorded 24 hours 
after first mixing the formulations. Our control formulation (1) prepared from α-TCP and 
hydroxyapatite suspended in disodium phosphate solution had a compressive modulus of ca. 100 
MPa, a compressive strength of ca. 12 MPa and a modulus of resilience of ca. 4000 J/m3 (Table 
1, Figure 3 and S3). Replacement of the disodium phosphate solution with bioactive PPP 
(formulation 2) resulted in a formulation that did not set within 24 hours and was therefore not 
investigated further. Interestingly, the addition of disodium phosphate (4 wt %) to the bioactive 
PPP (i.e., formulation 3) promoted setting of the α-TCP, resulting in a cement with a 
compressive modulus and compressive strength of ca. 55 MPa and 3 MPa respectively, and a 
modulus of resilience of ca. 40 J/m3. Further reduction of the PPP volume within cement 
formulation 4 produced a cement with a compressive modulus of ca. 440 MPa, a compressive 
strength of ca. 22 MPa and a modulus of resilience of ca. 5400 J/m3. We found that the addition 
of PGA sutures to α-TCP and hydroxyapatite suspended in disodium phosphate solution (i.e., 
formulation 5) yielded composites with diminished compressive modulus and strength (ca. 50 
MPa and 4 MPa respectively) and modulus of resilience (of ca. 510 J/m3), relative to the 
analogous formulation (1) without the sutures. Formulation 6, incorporating equal quantities of 
disodium phosphate, CMC and gelatin, a small amount of PPP and Monofyl® sutures resulted in 
composites with a compressive modulus and strength of ca. 54 MPa and 5 MPa respectively, and 
a modulus of resilience of ca. 40 J/m3. Formulation 7, incorporating more gelatin to formulation 
6 (at the expense of the disodium phosphate), resulted in composites with a compressive 
modulus and strength of ca. 82 MPa and 4 MPa respectively, and a modulus of resilience of ca. 
250 J/m3. Formulation 8, based on formulation 4 with the addition of 0.8 wt % Monofyl® 
sutures, resulted in composites with a compressive modulus and strength of ca. 98 MPa and 8 
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MPa respectively, and a modulus of resilience of ca. 1130 J/m3. The addition of a greater 
quantity of sutures (1.5 wt %, i.e., formulation 9) moderately decreased the compressive modulus 
and strength to ca. 87 MPa and 7 MPa respectively, however the modulus of resilience increased 
to ca. 2130 J/m3, although this was not a statistically significant improvement. Finally, 
formulation 10 (formulation 8 with extra disodium phosphate at the expense of PPP) had further 
improved mechanical properties, with a compressive modulus and strength of ca. 265 MPa and 
21 MPa respectively, similar to formulation 4. 
CPCs are promising replacements for PMMA-based cements. We studied the mass change of a 
selection of the samples incubated in PBS at 37 oC over the period of two weeks for three of the 
compositions studied: formulation 1 without sutures, formulation 5 with PGA sutures and 
formulation 8 with Monofyl® sutures, chosen toconfirm their stability with respect to mass loss 
for more than one week (Figure S4) after which the inflammatory response phase is complete 
and renewal and remodeling begins.38 Formulation 1, without sutures was observed to swell and 
increase in mass moderately (ca. 1 to 2 %) over the first few days before gradually decreasing in 
mass to ca. 98 % of their initial mass after one week and plateauing at ca. 97 % of their initial 
mass after two weeks. Formulation 5 including PGA sutures was found to degrade more quickly, 
to ca. 94 % of their initial mass after 1 week, and to ca. 93 % of their initial mass after 2 weeks. 
By contrast, formulation 8 including Monofyl® sutures, CMC and a small amount of PPP, were 
found to be more stable to mass loss and remained swollen by ca. 2 % after 2 weeks. While we 
expect that the composites would behave differently in the biological milieu in vivo in which 
there are a variety of other factors at play, this gives some indication that the cement 





We sought to develop CPC-based bone cements for the healing of bone defects with regenerative 
biomaterials. The composite materials incorporated α-TCP and hydroxyapatite with 
combinations of biopolymer-based thickeners, a blood plasma wetting agent, and biodegradable 
polymer-based sutures. Calcium phosphates are major components of bones and teeth, typically 
in the form of hydroxyapatite, which represents 2 wt % of the calcium phosphate content of the 
composites described here. Hydroxyapatite is however not self-setting, consequently the majority 
of the solids in these composites was self-setting α-TCP (98 wt % of the calcium phosphate 
content of the composites described here) which is a biocompatible calcium phosphate that 
hydrolyses to form calcium-deficient hydroxyapatite.34 
The α-TCP used herein was ground to a size that yielded reproducible mechanical properties.18,19 
Bone cement formulations require liquid-based wetting agents to suspend the calcium 
phosphates within. Blood plasma, such as platelet poor plasma (PPP) is a source of growth 
factors known to promote the formation of new bone matrix39, 40 and was one of the components 
incorporated in some of the wetting agent formulations investigated. Aqueous solutions of 
disodium phosphate (4 wt %) have been shown to promote setting of α-TCP41 and was used in 
the majority of the wetting agent formulations. Various combinations of biopolymers including 
CMC and gelatin were used to viscosify the suspensions42 and potentially promote cell 
adhesion.43 Furthermore, we sought to counteract the tendency of calcium phosphate cements 
tend to fail by brittle fracture and crack propagation23, 26 through reinforcement with 
biodegradable fibers,23, 26, 44-51 using either Monofyl® or PGA sutures. While in the short term 
the 4-0 sutures were intended to reinforce the composites, their long term degradation in vivo has 
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the potential to leave channels of ca. 150 µm within the cement matrix that would be suitable for 
the infiltration of osteoclasts which may promote remodeling of the CPC, possibly facilitating 
vascularization.16, 52-54  Since the mechanical strain and accordingly turnover rate of low load 
bearing bone tissue such as sinuses is low, and apatitic cements resorb slowly, we expect bone 
ingrowth to exceed the degradation of our formulations.28, 55 While coordinating CPC 
degradation rates with the rate of bone ingrowth is important, it would also be necessary to 
assess the mechanical stability of CPC treated bone over longer time periods which is outside the 
scope of the present study. 
For low load bearing applications such as sinus augmentation or filling extraction sites, we 
require CPC formulations with Young’s moduli of ca. 0.05-1GPa.17 Consequently we assessed 
the compressive moduli and strengths of the CPC formulations via compressive extension tests 
(Table 1). 
Our control CPC formulation (1) prepared from α-TCP and hydroxyapatite suspended in 
disodium phosphate solution, was expected to be the least bioactive, and had a compressive 
modulus of ca. 100 MPa and a compressive strength of ca. 11 MPa, which would be acceptable 
for low load bearing applications.17, 18 Complete replacement of the disodium phosphate solution 
with bioactive PPP (formulation 2) yielded a formulation that did not set within 24 hours; 
however, the addition of disodium phosphate (4 wt %) to the PPP (i.e., formulation 3) promoted 
setting of the α-TCP,41 yielding a conceptually bioactive CPC with a compressive modulus and 
compressive strength of ca. 55 MPa and 3 MPa respectively, which may also be clinically 
relevant. Viscosification of the CPC formulations was achieved through the addition of CMC, 
and formulation 4, including disodium phosphate and PPP, yielded a bioactive CPC with a 
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compressive modulus of ca. 440 MPa, a compressive strength of ca. 22 MPa and a modulus of 
resilience of ca. 5400 J/m3, the highest of all of the formulations reported herein. With a view to 
further enhance the long term potential bioactivity of the cement formulations we investigated 
the addition of biodegradable sutures. Inclusion of 4-0 biodegradable sutures in the formulations 
has the potential to reinforce the CPC composites for some time after their application at the site 
of the bone defect, and moreover, the potential to leave channels of ca. 150 µm within the CPC 
matrix after their degradation. These channels, in vivo, would allow for the infiltration of 
osteoclasts and promote remodeling of the cement.16, 52-54 We found that the addition of PGA 
sutures to α-TCP and hydroxyapatite suspended in disodium phosphate solution (i.e., formulation 
5) yielded CPC composites with diminished compressive modulus and strength (ca. 50 MPa and 
4 MPa respectively) relative to the analogous formulation (1) without the sutures. We postulate 
this observation to be a result of the interference of the L-lysine and/or the monolaurin coating 
on the PGA sutures with the CPC setting process. Monofyl® sutures represent an attractive 
alternative to PGA sutures because they are uncoated and the composites are stable with respect 
to mass loss for more than one week (Figure S4) after which the inflammatory response phase is 
complete and renewal and remodeling begins,58 consequently, we utilized these in the rest of the 
CPC formulations. 
Bones are rich in cell-adhesive collagens, and the inclusion of gelatin (partially hydrolyzed 
collagen) to the formulations was intended to render them simultaneously viscous and more cell 
adhesive.27, 59, 60 Formulation 6, incorporating equal quantities of disodium phosphate, CMC and 
gelatin, a small amount of PPP and Monofyl® sutures yielded CPC composites with a 
compressive modulus and strength of ca. 54 MPa and 5 MPa respectively. Formulation 7, 
incorporating more gelatin to formulation 6 (at the expense of the disodium phosphate), yielded 
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CPC composites with a compressive modulus and strength of ca. 82 MPa and 4 MPa, 
respectively. Formulation 8, based on formulation 4 with the addition of 0.8 wt % Monofyl® 
sutures, yielded CPC composites with a compressive modulus and strength of ca. 98 MPa and 8 
MPa respectively, and a modulus of resilience of ca. 1130 J/m3, which was markedly lower than 
formulation 4 without the sutures. The addition of a greater quantity of sutures (1.5 wt %), 
yielding formulation 9, moderately decreased the compressive modulus and strength to ca. 87 
MPa and 7 MPa respectively, the modulus of resilience was observed to increase to ca. 2130 
J/m3 , although this was not a statistically significant improvement. Finally, formulation 10 
(formulation 8 with extra disodium phosphate at the expense of PPP) had further improved 
mechanical properties, with a compressive modulus and strength of ca. 265 MPa and 21 MPa 
respectively, and a modulus of resilience of ca. 1420 J/m3, similar to formulation 4.  
Considering the mechanical properties for all cements in Table 1, we find formulations 1, 3, 4, 5, 
6, 7, 8, 9 and 10 to be suitable for low load bearing applications, of which formulations 4 and 10 
have significantly improved mechanical properties as well as regenerative potential.    We 
observed rheological interactions that prevented CPC setting when using high volumes of PPP 
wetting agent, and we suggest therefore that further characterization of blood and CPC 
interactions are necessary, yet we overcame this limitation using a 4% disodium phosphate 
solution, CMC, and lower volumes of PPP. 
CONCLUSIONS 
Bone cements enhanced by regenerative strategies are promising biomaterials for the healing of 
bone defects. The preparation of injectable CPC-based composites incorporating α-TCP, 
hydroxyapatite, biopolymer-thickened wetting agents, and optionally, biodegradable polymer-
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based sutures yields biodegradable bone-like composites, of which, formulations 1, 3, 4, 5, 6, 7, 
8, 9 and 10 had compressive moduli suitable for low load bearing applications.18 While we did 
not observe a higher modulus of resilience by suture reinforcement in this study, we hypothesize 
the surface modifications of suture inclusions may be able to increase interfacial strength with 
the CPC composite, as would inclusion of longer sections of sutures. This increased strength may 
facilitate a higher modulus of resilience in the composite cement formulation and facilitate the 
application of such composites in medium and high load bearing applocations. The CPC-based 
bone cements with regenerative potential reported herein have potential as replacements for non-
resorbable cements such as those based on PMMA and conventional CPC formulations without 
the potential for macropore formation,19 with advantages including the potential for co-
administration of cells, drugs and proteins without thermal damage.61-64 Furthermore, simple 
alterations to the CPC compositions of the cement formulations will facilitate further modulation 
of their osteoconductive and surgical handling properties. Future studies will focus on 
optimization of CPC formulations for injection and characterizing the dynamic nature of CPC 
mechanical properties in vitro. Moreover, we will optimize suture lengths/loadings and 
characterize the long term degradation of the resulting scaffolds. 
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Table 1. Compositions and mechanical properties of the CPC formulations.  
Figure 1. A) The FTIR spectrum the KBr disc of α-TCP recorded in transmission mode. B) The 
FTIR spectrum of pure α-TCP (Figure 1 B) recorded in ATR mode. C) XRD spectrum of α-TCP. 
Figure 2. α-TCP powder. A) Scanning Electron Microscope (SEM) image of the same powder 
obtained on a Zeiss Supra 40 VP SEM (scale bar represents 200 µm). B) ImageJ-derived contour 
maps of SEM images from which the particle size distribution of α-TCP particles was 
determined. 
Figure 3. Mechanical properties of the CPC formulations described here. A) Box plot for 
compressive modulus data, * = significant from group 4; ** = significant from group 10. B) Box 
plot for ultimate strength data, * = significant from group 1; ** = significant from group 4 and 
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10. C) Box plot for modulus of resilience data, * = significant from group 1; ** = significant 
from group 4. 
Figure S1. α-TCP powder. A) Photograph of the solid isolated from the furnace. Image width = 5 
cm. B) Photograph of the powder obtained after using the Mixer Mill MM 300 for 30 minutes. 
Image width = 5 cm. 
Figure S2. α-TCP powder  particle surface area distribution. 
Figure S3. Visual representation of the results of Tukey multiple comparison analysis of the 
mechanical properties of the CPC formulations described here. A) Compressive modulus. B) 
Strength. C) Modulus of resilience. 
Figure S4. In Vitro Degradation Study. Black bars represent formulation 1. Dark grey bars 
represent formulation 5 with PGA sutures. Light grey bars represent formulation 8 with 
Monofyl® sutures. 
